Sprint Bioscience (Sweden) Performance
| SPRINT Stock | SEK 1.67 0.06 3.73% |
The entity has a beta of 0.21, which indicates not very significant fluctuations relative to the market. As returns on the market increase, Sprint Bioscience's returns are expected to increase less than the market. However, during the bear market, the loss of holding Sprint Bioscience is expected to be smaller as well. Sprint Bioscience right now has a risk of 4.82%. Please validate Sprint Bioscience potential upside, as well as the relationship between the kurtosis and day typical price , to decide if Sprint Bioscience will be following its existing price patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Sprint Bioscience AB has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong basic indicators, Sprint Bioscience is not utilizing all of its potentials. The newest stock price disturbance, may contribute to short-term losses for the investors. ...more
| Begin Period Cash Flow | 27.1 M | |
| Total Cashflows From Investing Activities | -2.7 M |
Sprint |
Sprint Bioscience Relative Risk vs. Return Landscape
If you would invest 176.00 in Sprint Bioscience AB on October 20, 2024 and sell it today you would lose (9.00) from holding Sprint Bioscience AB or give up 5.11% of portfolio value over 90 days. Sprint Bioscience AB is generating 0.0294% of daily returns and assumes 4.8155% volatility on return distribution over the 90 days horizon. Simply put, 42% of stocks are less volatile than Sprint, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Sprint Bioscience Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Sprint Bioscience's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Sprint Bioscience AB, and traders can use it to determine the average amount a Sprint Bioscience's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0061
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | SPRINT |
Estimated Market Risk
| 4.82 actual daily | 42 58% of assets are more volatile |
Expected Return
| 0.03 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| 0.01 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Sprint Bioscience is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Sprint Bioscience by adding Sprint Bioscience to a well-diversified portfolio.
Sprint Bioscience Fundamentals Growth
Sprint Stock prices reflect investors' perceptions of the future prospects and financial health of Sprint Bioscience, and Sprint Bioscience fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Sprint Stock performance.
| Return On Equity | -1.09 | |||
| Return On Asset | -0.59 | |||
| Operating Margin | (76.00) % | |||
| Current Valuation | 24.98 M | |||
| Shares Outstanding | 69.8 M | |||
| Price To Earning | 32.79 X | |||
| Price To Book | 2.61 X | |||
| Price To Sales | 27.09 X | |||
| Revenue | 35.11 M | |||
| EBITDA | (24.22 M) | |||
| Cash And Equivalents | 13.82 M | |||
| Cash Per Share | 1.19 X | |||
| Debt To Equity | 32.20 % | |||
| Book Value Per Share | 0.63 X | |||
| Cash Flow From Operations | (40.12 M) | |||
| Earnings Per Share | (0.75) X | |||
| Total Asset | 79.14 M | |||
| Retained Earnings | (39 M) | |||
| Current Asset | 25 M | |||
| Current Liabilities | 21 M | |||
About Sprint Bioscience Performance
By analyzing Sprint Bioscience's fundamental ratios, stakeholders can gain valuable insights into Sprint Bioscience's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Sprint Bioscience has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Sprint Bioscience has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Sprint Bioscience AB develops pharmaceutical products in the areas of cancer and metabolism. Sprint Bioscience AB was founded in 2009 and is based in Huddinge, Sweden. Sprint Bioscience operates under Pharmaceuticals And Biosciences classification in Sweden and is traded on Stockholm Stock Exchange.Things to note about Sprint Bioscience performance evaluation
Checking the ongoing alerts about Sprint Bioscience for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Sprint Bioscience help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Sprint Bioscience may become a speculative penny stock | |
| Sprint Bioscience had very high historical volatility over the last 90 days | |
| The company reported the revenue of 35.11 M. Net Loss for the year was (25.08 M) with profit before overhead, payroll, taxes, and interest of 24.59 M. | |
| Sprint Bioscience AB has accumulated about 13.82 M in cash with (40.12 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.19. | |
| Roughly 35.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing Sprint Bioscience's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Sprint Bioscience's stock is overvalued or undervalued compared to its peers.
- Examining Sprint Bioscience's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Sprint Bioscience's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Sprint Bioscience's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Sprint Bioscience's stock. These opinions can provide insight into Sprint Bioscience's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Sprint Stock analysis
When running Sprint Bioscience's price analysis, check to measure Sprint Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sprint Bioscience is operating at the current time. Most of Sprint Bioscience's value examination focuses on studying past and present price action to predict the probability of Sprint Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sprint Bioscience's price. Additionally, you may evaluate how the addition of Sprint Bioscience to your portfolios can decrease your overall portfolio volatility.
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios |